nimodipine   Click here for help

GtoPdb Ligand ID: 2523

Synonyms: BAY-E-9736 | Nimotop®
Approved drug
nimodipine is an approved drug (FDA (1988))
Compound class: Synthetic organic
Comment: Nimodipine is a dihydropyridine calcium channel blocker.
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: nimodipine

2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 10
Topological polar surface area 117
Molecular weight 418.17
XLogP 4
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COCCOC(=O)C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OC(C)C)C
Isomeric SMILES COCCOC(=O)C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OC(C)C)C
InChI InChI=1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3
InChI Key UIAGMCDKSXEBJQ-UHFFFAOYSA-N
Bioactivity Comments
Nimodipine is widely described as a L-type calcium channel inhibitor, however it also blocks T-type calcium channel (CaV3.1-3.3) currents. The pKi for CaV3.2 is 5.25 (~5.6 μM).
Selectivity at ion channels
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
Cav1.2 Rn Gating inhibitor Antagonist 6.8 pIC50 - 5
pIC50 6.8 [5]
Voltage: -80.0 mV
Cav1.3 Rn Gating inhibitor Antagonist 5.7 – 6.6 pIC50 - 2,5
pIC50 5.7 – 6.6 [2,5]
Voltage: -80.0 – -40.0 mV
Cav1.1 Hs Gating inhibitor Antagonist ~6.0 pIC50 -
pIC50 ~6.0 (IC50 ~1x10-6 M)
Voltage: -70.0 mV
Cav1.4 Hs Gating inhibitor Antagonist ~6.0 pIC50 -
pIC50 ~6.0 (IC50 ~1x10-6 M)
Voltage: -70.0 mV
P2X4 Hs Allosteric modulator Positive - - - 3
[3]
CFTR Hs Activator Potentiation - - -
Selectivity at nuclear hormone receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
Mineralocorticoid receptor Primary target of this compound Hs Antagonist Antagonist 6.8 pIC50 - 1
pIC50 6.8 (IC50 1.6x10-7 M) inhibition of aldosterone-induced luciferase activity in a reporter system driven by the mineralocorticoid receptor ligand binding domain [1]
Targets where the ligand is described in the comment field
Target Comment